Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 5
2007 4
2008 3
2009 1
2010 4
2011 2
2013 2
2015 8
2016 14
2017 13
2018 4
2019 4
2020 3
2021 5
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma.
Aoki T, Kudo M, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Tsurusaki M, Nishida N. Aoki T, et al. Among authors: ida h. Liver Cancer. 2023 May 11;13(1):56-69. doi: 10.1159/000531024. eCollection 2024 Feb. Liver Cancer. 2023. PMID: 38344443 Free PMC article.
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.
Kudo M, Aoki T, Ueshima K, Tsuchiya K, Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, Ida H, Nishida N, Ogawa C, Tomonari T, Nakamura N, Kuroda H, Takebe A, Takeyama Y, Hidaka M, Eguchi S, Chan SL, Kurosaki M, Izumi N. Kudo M, et al. Among authors: ida h. Liver Cancer. 2023 Feb 7;12(4):321-338. doi: 10.1159/000529574. eCollection 2023 Sep. Liver Cancer. 2023. PMID: 37901197 Free PMC article.
Progression from early to advanced stage of immune-related cholangitis.
Hagiwara S, Yoshida T, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Aoki T, Morita M, Cishina H, Komeda Y, Yoshida A, Hayashi H, Nakagawa K, Kudo M. Hagiwara S, et al. Among authors: ida h. Hepatol Res. 2022 Oct;52(10):888-892. doi: 10.1111/hepr.13817. Epub 2022 Aug 15. Hepatol Res. 2022. PMID: 35860944
Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria.
Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Aoki T, Morita M, Chishina H, Komeda Y, Yoshida A, Park AM, Sato M, Kawada A, Nakano H, Nakagawa H, Kudo M. Hagiwara S, et al. Among authors: ida h. Sci Rep. 2022 Apr 12;12(1):6100. doi: 10.1038/s41598-022-10089-z. Sci Rep. 2022. PMID: 35414164 Free PMC article.
Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma.
Aoki T, Nishida N, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Yamada A, Sofue K, Tsurusaki M, Kudo M. Aoki T, et al. Among authors: ida h. Liver Cancer. 2021 Aug 19;10(6):615-628. doi: 10.1159/000518048. eCollection 2021 Nov. Liver Cancer. 2021. PMID: 34950184 Free PMC article.
75 results